Why Develop the Ocular Delivery System for Gene Therapy

The number of effective gene therapies for ocular diseases is growing rapidly. Most clinical studies of ocular gene therapy use viral and non-viral vectors, and are administered to the eye by different means, such as intravitreal, subretinal, and suprachoroidal routes. To demonstrate stable and prolonged gene expression with minimal toxicity, a successful gene therapy is dependent on effective gene or drug transfer to target cell. At present, the main obstacle to gene therapy for eye diseases is not the lack of ideal genes, but the lack of safe and effective methods to selectively deliver genes to target cells and tissues. Therefore, it is extremely critical for researchers and drug development companies to develope an efficient and stable gene delivery system.

Fig. 1. Ocular gene therapy and RNA-based approaches in clinical trials. (Bordet T, et al., 2019)

Service Overview

With extensive experience in gene therapy development for ocular diseases, Ace Therapeutics develops customized delivery systems for ocular diseases for clients worldwide. We have a fully specialized research team responsible for the development and implementation of your entire project. You will benefit from our scientists' scientific experience and advice to achieve your research goals faster. Our scientists will stay in touch and communicate with you at all times to ensure key development milestones are achieved.

• Development of Dendrimers As Gene Delivery Systems for Ocular Diseases

Due to their nanoscale size, low host immunogenicity, safety, and low cost, dendrimers can be combined with genetic material for efficient gene delivery. Here, we provide a fast, efficient and reliable method to functionalize the surface of dendrimers for your convenience.

• Development of Liposomes As Gene Delivery Systems for Ocular Diseases

Liposomes are nanovesicular or microvesicular drug or gene delivery systems ranging in size from 0.025 to 10 µm that contain a single lipid bilayer or multiple intertwined lipid bilayers. Cationic liposomes containing positively charged components are used as nonviral gene delivery systems. Ace Therapeutics has developed a variety of cationic liposomes that yield long-term expression and durable gene transfer efficiencies, allowing them to accelerate your ocular cell therapy applications.

Ace Therapeutics is a leading global biotechnology company with extensive experience in eye disease research. Based on our deep understanding of the specific challenges of developing gene therapy products, we provide highly effective gene delivery system solutions for ocular diseases to our global customers. You will benefit from our expert scientists' scientific experience and advice to achieve your development goals faster and with a higher chance of success. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

Reference

1. Bordet T, Behar-Cohen F. Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives. Drug Discov Today. 2019;24(8):1685-1693.

• AAV Vector Development Services for Ocular Nucleic Acid-Based Therapy
• Lentiviral Vector Development Services for Ocular Nucleic Acid-Based Therapy
• Non-Viral Vector Development Services for Ocular Nucleic Acid-Based Therapy
• Recombinant Adeno-Associated Virus Vector Development Services for Ocular Nucleic Acid-Based Therapy
• CRISPR/Cas9 Gene Editing Services for Ocular Nucleic Acid-Based Therapy
• Safety and Toxicology Assessment Services for Ocular Nucleic Acid-Based Therapy
• Potency Testing Services for Ocular Nucleic Acid-Based Therapy

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit